Pharmaceutical Research articles highlight advancements in 3D printing.
The recently published Pharmaceutical Research theme 3D Printing of Pharmaceutical and Medical Applications: A New Era, edited by Dionysios Douroumis, provides a comprehensive discussion on 3D printing technologies used for soft materials, food, pharmaceutical dosage forms, and biomedical applications.
3D printing fabricates objects through layer-by-layer technology via computer software. In the pharmaceutical industry, 3D printing will allow for more on-demand drug creation. This could be beneficial for personalized medicine and for drug development on-site in remote geographical locations. The first 3D-printed drug approved by the Food and Drug Administration was Spritam by Aprecia Pharmaceuticals, LLC, in 2015.
This theme highlights the challenges of using 3D printing technologies and regulatory hurdles, and it provides current achievements in 3D printing, including personalized dosage forms, implants, and regenerative medicine.
Articles in this theme also showcase new developments in 3D printing, including a screening process for the selection and design of filaments for fusion deposition modeling (FDM) with suitable mechanical properties; immediate release 3D-printed tablets produced via FDM by processing a thermos-sensitive drug; and cell exclusion spacers with various geometries for use in cell motility studies allowing on-demand assays.
Read more about the history of 3D printing and future applications in 3D Printing of Pharmaceutical and Medical Applications: A New Era. Many articles in this theme are open access—make sure to share them with your colleagues.
AAPS journals
Pharmaceutical Research, The AAPS Journal, and AAPS PharmSciTech are available with AAPS membership.
Log in
Click through once on any journal cover to gain full-text access to all articles.
AAPS Open articles
Pharmaceutical Research Seeks Editor-in-Chief
The American Association of Pharmaceutical Scientists (AAPS) journal Pharmaceutical Research, published in partnership with Springer Nature, is taking applications for editor-in-chief. This journal is committed to publishing novel research that is mechanism-based, hypothesis-driven, and addresses significant issues in drug discovery, development, and regulation. Are you interested in applying or recommending this position to a colleague?
LEARN MORE
.